Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of CLDN6 CAR-T with or without CLDN6 RNA-LPX in CLDN6-positive solid tumors
NL-OMON58728Phase 1Active, not recruiting
- Sponsor
- BioNTech SE
- Start
- Aug 2020
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BNT211 and cldn6 modrna-lpx in Nonhematologic neoplasms, sponsored by BioNTech SE. Started Aug 2020; status: active, not recruiting.
02
Drugs
BNT211cldn6 modrna-lpx
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON58728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58728.